Verve Therapeutics
VERV
VERV was delisted on the 24th of July, 2025.
69 hedge funds and large institutions have $2.25B invested in Verve Therapeutics in 2021 Q2 according to their latest regulatory filings, with 69 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
81.71% more ownership
Funds ownership: 0% → 81.71% (+82%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AI
Alphabet Inc
Mountain View,
California
|
+$456M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$165M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$143M |
| 4 |
CC
Casdin Capital
New York
|
+$126M |
| 5 |
RG
Redmile Group
San Francisco,
California
|
+$80.4M |
Top Sellers
VERV Hedge Fund Activity: Q2 2021 in Review
69 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Verve Therapeutics (VERV) for Q2 2021, worth a combined $2.25B.
Buyers outnumbered sellers: 69 funds opened new VERV positions and 0 closed out — a net gain of 69 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Alphabet Inc, opening a new position worth an estimated $456M.
- 69 institutional investors held Verve Therapeutics (VERV) as of Q2 2021, up from 0 in Q1 2021.
- Funds reported $2.25B of Verve Therapeutics stock for Q2 2021.
- 69 funds opened new Verve Therapeutics positions in Q2 2021 and 0 closed out, a net change of +69 holders.
- The largest Verve Therapeutics buyer in Q2 2021 was Alphabet Inc, an estimated $456M added.
Based on aggregated 13F filings for Q2 2021.